新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景

国际肿瘤学杂志››2023,Vol. 50››Issue (2): 122-125.doi:10.3760/cma.j.cn371439-20221024-00025

新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景

张雨潇, 张连生(), 李莉娟()

兰州大学第二医院血液科，兰州 730000

收稿日期:2022-10-24修回日期:2022-12-12出版日期:2023-02-08发布日期:2023-03-22
通讯作者:张连生，Email： zhanglsh@lzu.edu.cn ；李莉娟，Email： doctorjuan@sina.com
基金资助:
国家血液系统疾病临床医学研究中心委托课题(2021WWA01);兰州大学第二医院萃英科技创新项目(CY2017-ZD04);兰州大学第二医院萃英科技创新项目(CY2019-MS14)

Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma

Zhang Yuxiao, Zhang Liansheng(), Li Lijuan()

Department of Hematology，Lanzhou University Second Hospital，Lanzhou 730000，China

Received:2022-10-24Revised:2022-12-12Online:2023-02-08Published:2023-03-22
Contact:Zhang Liansheng，Email： zhanglsh@lzu.edu.cn ；Li Lijuan，Email： doctorjuan@sina.com
Supported by:
National Clinical Medical Research Center for Hematological Diseases Subject of Commission(2021WWA01);Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital(CY2017-ZD04);Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital(CY2019-MS14)

摘要/Abstract

摘要：

T细胞免疫球蛋白和免疫受体酪氨酸抑制性基序结构域（TIGIT）是近年新兴的免疫检查点蛋白，研究表明TIGIT能够使免疫细胞功能障碍，减弱抗肿瘤效应，导致肿瘤免疫耐受与免疫逃逸。通过阻断TIGIT可以逆转免疫细胞衰竭，发挥抗肿瘤效应，有望成为新一代多发性骨髓瘤治疗靶点。

张雨潇, 张连生, 李莉娟. 新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景[J]. 国际肿瘤学杂志, 2023, 50(2): 122-125.

Zhang Yuxiao, Zhang Liansheng, Li Lijuan. Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma[J]. Journal of International Oncology, 2023, 50(2): 122-125.

参考文献37

[1]	中国多发性骨髓瘤诊治指南不断完善[J]. 中华医学信息导报, 2022, 37(10): 4. DOI: 10.3760/cma.j.issn.1000-8039.2022.10.136. doi:10.3760/cma.j.issn.1000-8039.2022.10.136
[2]	郭红艳, 李莉娟, 黄紫莹, 等. 多发性骨髓瘤的免疫治疗研究现状[J]. 中国临床研究, 2021, 34(5): 676-680. DOI: 10.13429/j.cnki.cjcr.2021.05.024. doi:10.13429/j.cnki.cjcr.2021.05.024
[3]	王约拿, 刘佳, 李莉娟, 等. TIGIT对血液淋巴系统恶性肿瘤的免疫调节作用[J]. 中国临床研究, 2022, 35(6): 854-857. DOI: 10.13429/j.cnki.cjcr.2022.06.026. doi:10.13429/j.cnki.cjcr.2022.06.026
[4]	Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy[J]. Curr Oncol, 2022, 29(5): 3044-3060. DOI: 10.3390/curroncol29050247. doi:10.3390/curroncol29050247pmid:35621637
[5]	Shi AP, Tang XY, Xiong YL, et al. Immune checkpoint LAG3 and its ligand FGL1 in cancer[J]. Front Immunol, 2021, 12: 785091. DOI: 10.3389/fimmu.2021.785091. doi:10.3389/fimmu.2021.785091
[6]	Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy[J]. J Immunother Cancer, 2020, 8(2): e000957. DOI: 10.1136/jitc-2020-000957. doi:10.1136/jitc-2020-000957
[7]	Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 255. DOI: 10.1186/s13046-019-1259-z. doi:10.1186/s13046-019-1259-z
[8]	刘珊, 施怡玢, 尚晋, 等. TIGIT信号途径介导多发性骨髓瘤免疫逃逸的研究进展[J]. 现代免疫学, 2021, 41(6): 529-532.
[9]	Solomon BL, Garrido-Laguna I. TIGIT: a novel immunotherapy target moving from bench to bedside[J]. Cancer Immunol Immunother, 2018, 67(11): 1659-1667. DOI: 10.1007/s00262-018-2246-5. doi:10.1007/s00262-018-2246-5pmid:30232519
[10]	王立韬, 白丽. 用于肿瘤治疗的免疫检查点及其抑制剂研究进展[J]. 细胞与分子免疫学杂志, 2021, 37(7): 663-670. DOI: 10.13423/j.cnki.cjcmi.009232. doi:10.13423/j.cnki.cjcmi.009232
[11]	Rotte A, Sahasranaman S, Budha N. Targeting TIGIT for immuno-therapy of cancer: update on clinical development[J]. Biomedicines, 2021, 9(9): 1277. DOI: 10.3390/biomedicines 9091277. doi:10.3390/biomedicines 9091277
[12]	Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy[J]. J Immunother Cancer, 2022, 10(4): e004711. DOI: 10.1136/jitc-2022-004711. doi:10.1136/jitc-2022-004711
[13]	耿素霞, 杜欣. 2020年血液肿瘤靶向免疫检查点治疗研究进展[J]. 循证医学, 2021, 21(1): 45-49. DOI: 10.12019/j.issn.1671-5144.2021.01.012. doi:10.12019/j.issn.1671-5144.2021.01.012
[14]	Harjunpää H, Guillerey C. TIGIT as an emerging immune check-point[J]. Clin Exp Immunol, 2020, 200(2): 108-119. DOI: 10.1111/cei.13407. doi:10.1111/cei.13407pmid:31828774
[15]	Jeong BS, Nam H, Lee J, et al. Structural and functional charac-terization of a monoclonal antibody blocking TIGIT[J]. MAbs, 2022, 14(1): 2013750. DOI: 10.1080/19420862.2021.2013750. doi:10.1080/19420862.2021.2013750
[16]	Stanietsky N, Rovis TL, Glasner A, et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR[J]. Eur J Immunol, 2013, 43(8): 2138-2150. DOI: 10.1002/eji.201243072. doi:10.1002/eji.201243072pmid:23677581
[17]	Holder KA, Burt K, Grant MD. TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4+ T cells[J]. Clin Transl Immunology, 2021, 10(10): e1348. DOI: 10.1002/cti2.1348. doi:10.1002/cti2.1348
[18]	Sarhan D, Cichocki F, Zhang B, et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells[J]. Cancer Res, 2016, 76(19): 5696-5706. DOI: 10.1158/0008-5472.CAN-16-0839. doi:10.1158/0008-5472.CAN-16-0839pmid:27503932
[19]	Liu S, Zhang H, Li M, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells[J]. Cell Death Differ, 2013, 20(3): 456-464. DOI: 10.1038/cdd.2012.141. doi:10.1038/cdd.2012.141pmid:23154388
[20]	Yeo J, Ko M, Lee DH, et al. TIGIT/CD226 axis regulates anti-tumor immunity[J]. Pharmaceuticals (Basel), 2021, 14(3): 200. DOI: 10.3390/ph14030200. doi:10.3390/ph14030200
[21]	Kumar S. Natural killer cell cytotoxicity and its regulation by inhi-bitory receptors[J]. Immunology, 2018, 154(3): 383-393. DOI: 10.1111/imm.12921. doi:10.1111/imm.12921
[22]	Xu L, Liu L, Yao D, et al. PD-1 and TIGIT are highly co-expressed on CD8⁺T cells in AML patient bone marrow[J]. Front Oncol, 2021, 11: 686156. DOI: 10.3389/fonc.2021.686156. doi:10.3389/fonc.2021.686156
[23]	Minnie SA, Kuns RD, Gartlan KH, et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade[J]. Blood, 2018, 132(16): 1675-1688. DOI: 10.1182/blood-2018-01-825240. doi:10.1182/blood-2018-01-825240pmid:30154111
[24]	Ramsbottom KM, Hawkins ED, Shimoni R, et al. Cutting edge: DNAX accessory molecule 1-deficient CD8⁺T cells display immunological synapse defects that impair antitumor immunity[J]. J Immunol, 2014, 192(2): 553-557. DOI: 10.4049/jimmunol.1302197. doi:10.4049/jimmunol.1302197pmid:24337740
[25]	Jin HS, Ko M, Choi DS, et al. CD226hiCD8⁺T cells are a pre-requisite for anti-TIGIT immunotherapy[J]. Cancer Immunol Res, 2020, 8(7): 912-925. DOI: 10.1158/2326-6066.CIR-19-0877. doi:10.1158/2326-6066.CIR-19-0877
[26]	Joller N, Lozano E, Burkett PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses[J]. Immunity, 2014, 40(4): 569-581. DOI: 10.1016/j.immuni.2014.02.012. doi:10.1016/j.immuni.2014.02.012pmid:24745333
[27]	Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4[J]. Mol Cancer, 2019, 18(1): 155. DOI: 10.1186/s12943-019-1091-2. doi:10.1186/s12943-019-1091-2pmid:31690319
[28]	Guillerey C, Harjunpää H, Carrié N, et al. TIGIT immune check-point blockade restores CD8⁺T-cell immunity against multiple myeloma[J]. Blood, 2018, 132(16): 1689-1694. DOI: 10.1182/blood-2018-01-825265. doi:10.1182/blood-2018-01-825265pmid:29986909
[29]	卢惠, 王华芳. 免疫检查点分子TIGIT在血液恶性肿瘤中的研究进展[J]. 中国实验血液学杂志, 2021, 29(3): 993-997. DOI: 10.19746/j.cnki.issn1009-2137.2021.03.054. doi:10.19746/j.cnki.issn1009-2137.2021.03.054
[30]	Khan M, Arooj S, Wang H. NK cell-based immune checkpoint inhibition[J]. Front Immunol, 2020, 11: 167. DOI: 10.3389/fimmu.2020.00167. doi:10.3389/fimmu.2020.00167pmid:32117298
[31]	Lozano E, Mena MP, Díaz T, et al. Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma[J]. Clin Cancer Res, 2020, 26(17): 4688-4698. DOI: 10.1158/1078-0432.CCR-19-3673. doi:10.1158/1078-0432.CCR-19-3673pmid:32513837
[32]	Pazina T, MacFarlane AW 4th, Bernabei L, et al. Alterations of NK cell phenotype in the disease course of multiple myeloma[J]. Cancers (Basel), 2021, 13(2): 226. DOI: 10.3390/cancers13020226. doi:10.3390/cancers13020226
[33]	Ge Z, Peppelenbosch MP, Sprengers D, et al. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer[J]. Front Immunol, 2021, 12: 699895. DOI: 10.3389/fimmu.2021.699895. doi:10.3389/fimmu.2021.699895
[34]	邓铃. 多发性骨髓瘤患者骨髓间充质干细胞通过TIGIT/CD226调节NK细胞功能的研究[D]. 天津: 天津医科大学, 2020. DOI: 10.27366/d.cnki.gtyku.2020.000608. doi:10.27366/d.cnki.gtyku.2020.000608
[35]	Chauvin JM, Ka M, Pagliano O, et al. IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma[J]. Clin Cancer Res, 2020, 26(20): 5520-5533. DOI: 10.1158/1078-0432.CCR-20-0575. doi:10.1158/1078-0432.CCR-20-0575
[36]	Niu J, Maurice-Dror C, Lee DH, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer[J]. Ann Oncol, 2022, 33(2): 169-180. DOI: 10.1016/j.annonc.2021.11.002. doi:10.1016/j.annonc.2021.11.002
[37]	Lee JB, Ha SJ, Kim HR. Clinical insights into novel immune checkpoint inhibitors[J]. Front Pharmacol, 2021, 12: 681320. DOI: 10.3389/fphar.2021.681320. doi:10.3389/fphar.2021.681320